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ORAL VERSUS NASAL VASOPRESSIN IN THE TREATMENT OF 
NOCTURNAL ENURESIS IN 5- TO 12-YEAR-OLD CHILDREN
Abstract
Objective
Nocturnal enuresis is a common childhood problem and has various treatments. 
This study was carried out to compare oral and nasal vasopressin in the 
treatment of nocturnal enuresis in 5- to 12-year-old children who were referred 
to the Shahid Beheshti Clinic in 2008.
Materials & Methods
This study included 100 children (62 males and 38 females) with nocturnal 
enuresis. One group (50 patients) received 20 mcg nasal vasopressin which 
increased up to 40 mcg, depending on the patients’ response. The other group 
(50 patients) received 0.2 mg oral vasopressin which increased up to 0.4 mg. 
The patients were followed up for one month after response to the last dose of 
drug. Data were recorded in prepared forms and analyzed using Chi-Square 
and Fisher Test.  
Results
The success rate with oral and nasal method was 80% and 92%, respectively 
(P=0.08). Only 2% of the children had complications during the treatment; one 
child treated orally developed gastroenteritis and another child treated with 
the nasal method developed convulsions (P=1). Sixteen percent of the children 
treated with the oral method and 28% of the children treated with the nasal 
method had recurrence (P=0.148). 
Conclusion
Oral and nasal forms of vasopressin have equal therapeutic effects. However, 
oral form of the treatment has fewer serious side effects and is easier to use. 
Therefore, the use of oral medicine is recommended.
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Introduction
Nocturnal enuresis is involuntary voiding during the night’s sleep after the age of 
ﬁve when children usually have developed sphincter control. Its prevalence is 7% 
for ﬁve- year- old male children and 3% for females and is reduced to 3% and 2% at 
the age of 10, respectively. The most common form of the condition is the primary 
one in which the patient has no control over voiding at all while in secondary cases, 
enuresis re-appears after a period of normal control.        
The possible causes of enuresis are delay in the development of nervous pathways 
which control voiding, reduction of antidiuretic hormone (ADH) level during the 
night, genetic background, and ﬁnally some sleep disorders (1). It may lead to 
serious consequences, including lack of child’s self conﬁdence through self image 
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disorder, chronic anxiety, parental anxiety, physical 
punishment, and even child abuse (2).  
There are various pharmaceutical and non- 
pharmaceutical treatments. The basis of non- 
pharmaceutical treatments is on limiting the use of 
liquids at night or hours before sleeping, behavior 
therapy alarms with sensors that go off when they wet 
themselves, and ﬁnally motivation therapy including 
child encouragement and rewarding for dry nights (3). 
One of the oldest drugs used is imipramin, a tricyclic 
antidepressant which considerably controls symptoms 
during its use. However, recurrence is high after 
treatment is stopped (2). Vasopressin, the synthetic 
analogue of ADH, has been recently used effectively. 
There are many published trials of desmopressin for 
treating enuresis which conclude that desmopressin is 
superior to placebo in reducing the number of wet nights. 
To date, few adverse effects have been reported with 
desmopressin. Because minor side effects are common 
with the tricyclic antidepressants and because they are 
hazardous medications (due to the risk of accidental 
overdose), desmopressin may be a safer choice. This 
medicine was only available as nasal spray in the past 
but is now also available as oral tablets (4). Its nasal 
spray has a considerable effect on nocturnal enuresis. It 
showed to increase the average of dry nights from 0.6 to 
4.3 per week in a study in Finland (5) while its oral form 
reduced the number of wet nights for at least 1 night 
per week in a study in England (6). In other studies, 
the efﬁciency of oral tablets and nasal sprays have been 
reported to be almost equal (7,8). The drug is effective in 
patients who do not have a vasopressin diurnal rhythm 
and their maximum anti-diuretic hormone concentration 
decreases at night. It reaches maximum concentration 
0.5-1 hour after administration and has a half life of 4-6 
hours. It increases the renal reabsorption of water and 
reduces urine output during the night to less than the 
functional capacity of the bladder. Major side effects 
of the medicine include hyponatremia, headache, 
convulsions, and coma (1).        
Since the oral medicine has been recently introduced 
to the Iranian market and because the Desmopressine 
Argenine Vasopressin (DAVP) tablet has a good 
absorption, good biologic effects and few side effects 
similar to the intranasal spray, treatment with tablets is 
a good alternative to the intranasal route for primary 
nocturnal enuresis.
Materials & Methods
In a 12-month period in 2008, 100 children between 5 
and 12 years of age who were visited at the pediatrics 
clinics of Shahid Beheshti University for nocturnal 
enuresis (involuntary voiding at night at least once a 
week) were included in this study. Those with diabetes 
insipidus, diabetes mellitus, urinary tract infection, renal 
anomalies, psychologic problems, and simultaneous use 
of other nocturnal enuresis medicines were excluded 
from the study after appropriate evaluation by CBC, 
FBS, U/A, U/C tests, and renal sonography. After the 
approval of the ethics committee, informed consent 
forms were signed by either the patients or their 
parents. 
The sample population was 100 individuals based on the 
previous studies (7,9,10). Each child was given a number 
and ﬁfty numbers between 1 and 100 were randomly 
selected for oral treatment. The other 50 patients entered 
the nasal treatment group. Minimum oral or spray dose 
of 0.2 and 20 μg, respectively, started for the patients. 
The dose was increased by 50% after two weeks, and 
by 100% of the initial dose after another two weeks, 
if no acceptable response was observed. If no response 
was observed after these changes, they were identiﬁed 
as resistant, and the treatment stopped. Upon detecting 
improvement in any stage, the treatment continued for 
two weeks, tapered in the next two weeks and ﬁnally 
stopped. Recurrence was deﬁned as re-appearance of 
the symptoms during or after tapering. Interview with 
mothers or children was done by a trained nurse. Data 
including demographic characteristics of the patients, 
and the degree of recovery as complete (absence of 
nocturnal enuresis two weeks after treatment), or partial 
recovery (reduction of nocturnal enuresis by more than 
50%) were recorded in special forms and the results 
were compared in the two groups using chi-square and 
ﬁsher exact tests.
Results
Out of 100 children with nocturnal enuresis, 62 were 
male (31 in each group) and 38 were female (19 in each 
group) (P = 1). Seventy four percent of the involved 
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children were in the age range of 5 to 8 and 26% were 
in the age range of 9 to 12 years (Table 1). In 36% of the 
children, one parent had a history of nocturnal enuresis. 
Eighty percent of the children recovered after oral 
and 92% recovered after nasal treatment. Chi-square 
showed no statistical difference between the two modes 
of treatment (p<0.08) (Table2).    
Only 2% of children showed side effects, one in the oral 
and the other in the nasal group. The child in the nasal 
group developed convulsions (after hyponatremia) and 
the child in the oral group developed gastroenteritis. 
There was no signiﬁcant difference in side effects 
between the two groups (Table2). 
Nocturnal enuresis recurred in 22% of the children 
after treatment. Sixteen percent of the children with 
the oral and 28% with the nasal treatment experienced 
recurrence. Fisher test showed no signiﬁcant difference 
between these groups (p<0.148, Table2).
Discussion
The distribution of age and sex in our patients was 
similar to other studies (8,13, 14,15,16,17,18,19). One 
parent had a history of childhood nocturnal enuresis 
in 36% of the cases while most of the others studies 
(1,9,14,17,18,19,20) have reported rates even up to 85% 
(5,2). This may be due to the effect of ethnic and racial 
differences in different studies.
 In this study, 22% of the patients experienced recurrence. 
Recurrence rate was 16% in oral group and 28% in nasal 
group but the difference was not signiﬁcant (p<0.148). 
The recurrence rate has been reported up to 80-100% 
in two studies (21,22). It is believed that gradual 
discontinuation of the drugs may reduce the possibility 
of recurrence (23). 
Forty (80%) patients in the oral group and 46 (92%) in 
the nasal group showed improvement. The difference 
between the groups was not signiﬁcant (p<0.08) as 
shown in other studies (1,12,9,13,15,16,17,18). 
In a double blind study on 141 nocturnal enuresis 
patients between 5 and 17 years of age, 79% recovered 
after two weeks of treatment with vasopressin tablets 
(0.2mg) (9).
In a study, 15 children with nocturnal enuresis were 
treated with vasopressin tablets (0.2 mg) and 15 children 
were treated with 1 puff of vasopressin spray. Recovery 
(the number of dry nights per week) was signiﬁcant 
(between 41% and 52%, p<0.02) in both groups and the 
difference between the groups was not signiﬁcant (7).
In another study, 66 patients with nocturnal enuresis 
were treated with oral and nasal desmopressin and 
their recovery rate was then compared. No signiﬁcant 
difference was found. Ninety six percent of the patients 
took and tolerated desmopressin tablets well. It was 
concluded that the desmopressin tablet was an effective 
alternative in nocturnal enuresis in this study (10).
Only 2% of our children had side effects; one in the oral 
group developed gastroenteritis and one in the nasal 
group developed convulsion after hyponatremia. 
In a study on 34 children between 7 and 18 years of 
age in Singapore with 0.4 mg oral vasopressin for two 
weeks, no adverse effects were observed (11).
In a literature review including all the empirical 
studies from 1972 to 2005, out of 151 patients with 
hyponatremia, 145 were treated with nasal vasopressin 
and only 6 with oral vasopressin (8).
In Conclusion, Oral form of vasopressin is easier to use 
and is relatively safe. Therefore, it is recommended for 
the treatment of nocturnal enuresis in children. 
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Table 1. Prevalence distribution of nocturnal enuresis 
recovery versus treatment method,  age and sex
Treatment
Method          
 
Parameters
Oral Nasal PV
Male 25 (80.6) 28 (90.3) 0.473
Female 15 (78.9) 18 (94.7) 0.34
5-8 year 28 (82.4) 37 (92.5) 0.286
9-12 year 12 (75) 9 (90) 0.617
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Table 2. Prevalence distribution of complete and 
partial recovery of children with natural enuresis 
versus treatment method, Age & Sex
Treatment
Method
 
parameters
Nasal Oral PV
Recovery 46 (93) 40 (80) 0.08
Side effect 1 (2) 1 (20) 1
Recurrency 14 (28) 8 (16) 0.148
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